Session VI: Multiple Myeloma 

Session Chairs: Tom Martin, MD and Noopur Raje, MD

Frontline Therapy: TE – Current and Future – Where Should We Be Headed | Luciano J. Costa, MD, PhD | University of Alabama, Birmingham, Alabama, USA

Frailty Defines Frontline and Which IT at Relapse | Hira Mian, MD | McMaster University, Hamilton, Ontario, Canada

Sequencing Based on Mutations/Surface Expression? | Paola Neri, MD, PhD | University of Calgary, Calgary, Canada

Debate: CAR Should Be Used First in RR MM | Noopur Raje, MD | Massachusetts General Hospital, Boston, Massachusetts, USA

Debate: Bispecifics Should Be Used First in RR MM | Saad Z. Usmani, MD, MBA, FACP, FRCP, FASCO | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Updates - Amyloidosis and WM | Meletios A. Dimopoulos, MD | National and Kapodistrian University of Athens, Athens, Greece

ADCs and Non-BCMA Immuno Therapeutics | Robert Orlowski, MD, PhD | MD Anderson Cancer Center, Houston, Texas, USA

Next Generation: Degraders, Targeted Therapy – Where Do They Fit Best | Ajay K. Nooka, MD, MPH, FACP | Emory University, Winship Cancer Institute, Atlanta, Georgia, USA

Oral Abstract | TBD | Speaker | Affiliation